RASP (Actavia Life Sciences) Shares Outstanding (Basic Average): 771.81 Mil (As of Mar. 2024)


What is Actavia Life Sciences Shares Outstanding (Basic Average)?

Actavia Life Sciences RASP -87.50% Shares Outstanding (Basic Average) is 771.81 Mil as of Mar. 2024.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Actavia Life Sciences's average basic shares outstanding for the quarter that ended in Mar. 2024 was 771.81 Mil.

Actavia Life Sciences  (OTCPK:RASP) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

Actavia Life Sciences Shares Outstanding (Basic Average) Related Terms

Actavia Life Sciences Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for Actavia Life Sciences's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences Shares Outstanding (Basic Average) Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.91 68.91 68.91 111.43 578.02

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 588.52 771.81 770.27 771.81 771.81

Actavia Life Sciences Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 771.81 Mil mean?
Actavia Life Sciences (RASP) has a Shares Outstanding (Basic Average) of 771.81 Mil as of Mar. 2024. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' Shares Outstanding (Basic Average) too high?
Actavia Life Sciences' current Shares Outstanding (Basic Average) is 771.81 Mil.
How does Actavia Life Sciences' Shares Outstanding (Basic Average) compare to BWV and FNCH?
Actavia Life Sciences' Shares Outstanding (Basic Average) of 771.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Biotechnology company?
A good Shares Outstanding (Basic Average) depends on the Biotechnology industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Actavia Life Sciences and its competitors. Actavia Life Sciences's current Shares Outstanding (Basic Average) is 771.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current Shares Outstanding (Basic Average) of 771.81 Mil. The current Shares Outstanding (Basic Average) is 771.81 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current Shares Outstanding (Basic Average) is 771.81 Mil as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.